Growth differentiation factor 15 predicts advanced fibrosis in biopsy‐proven non‐alcoholic fatty liver disease

Background & Aims We explored whether growth differentiation factor 15 (GDF15) affects the histological severity of non‐alcoholic fatty liver disease (NAFLD) independent of insulin resistance. Methods In a biopsy‐proven NAFLD cohort, we measured serum GDF15 levels using enzyme‐linked immunosorbe...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Liver international 2018-04, Vol.38 (4), p.695-705
Hauptverfasser:	Koo, Bo Kyung, Um, Sung Hee, Seo, Dong Soo, Joo, Sae Kyung, Bae, Jeong Mo, Park, Jeong Hwan, Chang, Mee Soo, Kim, Jung Ho, Lee, Jieun, Jeong, Won‐Il, Kim, Won
Format:	Artikel
Sprache:	eng
Schlagworte:	Actin Adult Aged Animals Aspartate aminotransferase Biomarkers Biomarkers - blood Biopsy Body mass Body mass index Body size Cells, Cultured Collagen (type I) Confidence intervals Cross-Sectional Studies Diabetes mellitus Differentiation Fatty liver Female Fibrosis Gene expression growth differentiation factor 15 Growth Differentiation Factor 15 - blood Growth Differentiation Factor 15 - genetics Hepatocytes Humans Hypertension Immunoassays Insulin Insulin resistance Kupffer cells Liver Liver - pathology Liver Cirrhosis - blood Liver Cirrhosis - diagnosis Liver diseases Logistic Models Male Men Mice Middle Aged Muscles Non-alcoholic Fatty Liver Disease - complications Non-alcoholic Fatty Liver Disease - pathology Palmitic acid Patients Pharmacology Phosphorylation Prospective Studies Republic of Korea Risk Factors RNA, Messenger - analysis sarcopenia Severity of Illness Index Skeletal muscle SMAD Smad2 protein Smad3 protein Smoking Smooth muscle Stiffness
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background & Aims We explored whether growth differentiation factor 15 (GDF15) affects the histological severity of non‐alcoholic fatty liver disease (NAFLD) independent of insulin resistance. Methods In a biopsy‐proven NAFLD cohort, we measured serum GDF15 levels using enzyme‐linked immunosorbent assays. Results Among 190 subjects (mean age, 53 ± 14 years; men, 52.1%), 72 (men, 65.3%) and 78 (men, 44.9%) were diagnosed with biopsy‐proven non‐alcoholic fatty liver (NAFL) and non‐alcoholic steatohepatitis (NASH) respectively. GDF15 levels were significantly higher in NASH patients than in controls (P = .010) or NAFL patients (P = .001). Subjects with advanced fibrosis (≥F3) also showed higher GDF15 levels compared to the others (F0‐2; P
ISSN:	1478-3223 1478-3231
DOI:	10.1111/liv.13587